Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation

Oncology·MeSH: Lung Neoplasms
2 drugs in development·1 company·1 clinical trial

Drug Pipeline by Phase

Phase 3(1)
DrugCompany
JDQ443Novartis AG (NVS)
Phase 2(1)
DrugCompany
jdq443Novartis AG (NVS)

Frequently asked questions

How many drugs are in development for Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation?

BioSniper tracks 2 drugs in development for Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation across 1 company.

How many clinical trials target Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation?

There are 1 clinical trial targeting Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation tracked by BioSniper.

Deep-dive into Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation

Full trial data, competitive analysis, and AI-powered pipeline tracking.

Start Free Analysis
    Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation — Drugs in Development & Clinical Trials | BioSniper